Helmholtz Gemeinschaft

Search
Browse
Statistics
Feeds

Impact of early remission by induction therapy on allogeneic stem cell transplantation for acute myeloid leukemia with an intermediate risk karyotype in first complete remission

[thumbnail of Accepted manuscript (final draft)]
Preview
PDF (Accepted manuscript (final draft)) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
219kB

Item Type:Article
Title:Impact of early remission by induction therapy on allogeneic stem cell transplantation for acute myeloid leukemia with an intermediate risk karyotype in first complete remission
Creators Name:Hemmati, P.G., Terwey, T.H., Na, I.K., le Coutre, P., Jehn, C.F., Vuong, L.G., Dörken, B. and Arnold, R.
Abstract:For patients with acute myeloid leukemia (AML) early achievement of remission during induction treatment is an important predictor for long-term outcome irrespective of the type of consolidation therapy employed. Here, we retrospectively examined the prognostic impact of early remission (ER) versus delayed remission (DR) in a cohort of 132 AML patients with an intermediate risk karyotype undergoing allogeneic stem cell transplantation (alloSCT) in first complete remission (CR1). In contrast to patients showing DR, patients achieving ER had a significantly higher 3-year overall survival (OS) and disease-free survival (DFS) of 76% versus 54% (p=0.03) and 76% versus 53% (p=0.03). Likewise, three years after alloSCT the cumulative incidence of relapse (CI-R) was significantly lower in the ER subgroup as compared to patients achieving DR, i.e. 10% versus 35% (p=0.004), whereas non-relapse mortality (NRM) did not differ significantly. Multivariate analysis identified DR as an independent prognosticator for an inferior DFS (HR 3.37, p=0.002) and a higher CI-R (HR 3.55, p=0.002). Taken together, these data may indicate that the rapid achievement of remission predicts a favorable outcome in patients with intermediate risk AML undergoing alloSCT in CR1. In turn, the adverse effect of DR may not be fully overcome by alloSCT.
Keywords:Allogeneic Stem Cell Transplantation, Acute Myeloid Leukemia, Early Remission, Reduced Intensity Conditioning
Source:European Journal of Haematology
ISSN:0902-4441
Publisher:Wiley-Blackwell
Volume:94
Number:5
Page Range:431-438
Date:May 2015
Official Publication:https://doi.org/10.1111/ejh.12449
PubMed:View item in PubMed

Repository Staff Only: item control page

Downloads

Downloads per month over past year

Open Access
MDC Library